The startup has developed a liquid biopsy platform that utilizes PCR-based technology and bioinformatics to detect cancer biomarkers from blood samples, enabling early diagnosis and personalized treatment. This approach addresses the challenge of late-stage cancer detection by providing a minimally invasive, accurate, and cost-effective screening method.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Late-stage cancer detection poses a significant challenge, as the disease is often more difficult to treat at advanced stages. Traditional diagnostic methods can be invasive, costly, and lack the sensitivity needed for early detection.
Solution
The company offers a liquid biopsy platform designed for early and accurate cancer detection through a minimally invasive blood test. The platform combines advanced bioinformatics and proprietary PCR-based technology to identify epigenetic biomarkers in blood samples, even at early stages of cancer development. By applying big data analytics and AI, the platform selects the most relevant epigenetic biomarkers for each tumor type. The technology implements an enzymatic process to detect multiple biomarkers in a single PCR reaction, providing a simple workflow from blood sample to results.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and research institutions focused on early cancer detection and personalized medicine.
Features
- Proprietary PCR-based technology for detecting multiple biomarkers in a single reaction.
- Advanced bioinformatic framework utilizing big data and AI to identify and select epigenetic biomarkers specific to each tumor type.
- Minimally invasive liquid biopsy approach requiring only a routine blood sample.
- Simple workflow encompassing medical instruction, blood sample processing, laboratory analysis, and results reporting.